This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
Blood Cancer Journal Open Access 21 November 2022
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal Open Access 02 December 2021
-
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
Blood Cancer Journal Open Access 04 February 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011; 22: 1628–1635.
Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2012; 82: 141–149.
Van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG . How I treat plasma cell leukemia. Blood 2012; 120: 2376–2389.
Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27: 780–791.
Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010; 95: 804–809.
Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012; 26: 1091–1097.
Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288–294.
Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D’Arena G et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285–2290.
Musto P, Pietrantuono G, Guariglia R, Villani O, Martorelli MC, D'Auria F et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008; 32: 1637–1638.
Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk 2011; 11: 507–511.
Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia 2012; 26: 158–159.
Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia 2012; 26: 2398–2405.
D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012; 23: 1499–1502.
Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 2013; 19: 3130–3142.
Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res 2013; 19: 3247–3258.
Acknowledgements
This study was supported in part by research funding from Celgene to PM, on behalf of IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy. We wish to thank Sante Cundari, from Celgene, Italy, for his great contribution to the trial.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
PM received research financial support for this study and honoraria from Celgene. MTP, NC, FDR, FM, MO, AO, SB, MB and AP have received honoraria from Celgene. Other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Musto, P., Simeon, V., Martorelli, M. et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 28, 222–225 (2014). https://doi.org/10.1038/leu.2013.241
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.241
This article is cited by
-
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
Blood Cancer Journal (2022)
-
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
Blood Cancer Journal (2021)
-
A clinical perspective on plasma cell leukemia; current status and future directions
Blood Cancer Journal (2021)
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal (2021)
-
Extramedullary multiple myeloma
Leukemia (2020)